Stockreport

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of No...

enGene Holdings Inc.  (ENGN) 
PDF Business Wire Thu, January 30, 2025 at 2:00 PM GMT+1 8 min read In This Article ENGN ENGNW Detalimogene voraplasmid is a novel, investigational, pivotal-sta [Read more]